Advertisement
"This award recognizes the Canadian biotech company that has distinguisheditself from its peers with strong overall performance as a company,demonstrated leadership and significant achievement," said Peter Brenders,President and CEO of BIOTECanada. "BioMS Medical represents these qualitiesand is recognized as a leader in Canadian biotech."
Advertisement
"We are honored to have received this prestigious award from BIOTECanada,"said Kevin Giese, President and CEO of BioMS Medical. "In 2007 we achievedmany significant milestones as we advanced our lead drug for MS, MBP8298(dirucotide). This award recognizes the significant efforts made by thededicated employees at BioMS and the great progress we've made."
About BIOTECanada
-----------------
BIOTECanada is dedicated to the sustainable commercial development ofbiotechnology innovation in Canada. It is the national industry-fundedassociation with over 220 members representing the broad spectrum of biotechconstituents including emerging and established companies in the health,industrial, and agricultural sectors, as well as academic and researchinstitutions and other related organizations.
About BioMS Medical Corp.
-------------------------
BioMS Medical is a biotechnology company engaged in the development andcommercialization of novel therapeutic technologies. BioMS Medical's leadtechnology, MBP8298 (dirucotide), is for the treatment of multiple sclerosisand is being evaluated in two pivotal phase III clinical trials for secondaryprogressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in theUnited States. It additionally is being evaluated for relapsing remitting MSpatients in a Phase II trial in Europe entitled MINDSET-01. In December 2007,BioMS entered into a licensing and development agreement granting Eli Lillyand Company exclusive worldwide rights to MBP8298 (dirucotide) in exchange foran $87 million upfront payment, milestone payments and escalating royalties onsales. For further information please visit our website atwww.biomsmedical.com.
This press release may contain forward-looking statements, which reflectthe Company's current expectation regarding future events. Theseforward-looking statements involve risks and uncertainties that may causeactual results, events or developments to be materially different from anyfuture results, events or developments expressed or implied by suchforward-looking statements. Such factors include, but are not limited to,changing market conditions, the successful and timely completion of clinicalstudies, the establishment of corporate alliances, the impact of competitiveproducts and pricing, new product development, uncertainties related to theregulatory approval process and other risks detailed from time to time in theCompany's ongoing quarterly and annual reporting. Certain of the assumptionsmade in preparing forward-looking statements include but are not limited tothe following: that MBP8298 will continue to demonstrate a satisfactory safetyprofile in ongoing and future clinical trials; and that BioMS Medical Corp.will complete the respective clinical trials within the timelines communicatedin this release. We undertake no obligation to publicly update or revise anyforward-looking statements, whether as a result of new information, futureevents or otherwise.
SOURCE BioMS Medical Corp.
